EP0507948A1 - Monoklonaler antikörper, hybridome, ihre herstellung und verwendung - Google Patents
Monoklonaler antikörper, hybridome, ihre herstellung und verwendungInfo
- Publication number
- EP0507948A1 EP0507948A1 EP91901637A EP91901637A EP0507948A1 EP 0507948 A1 EP0507948 A1 EP 0507948A1 EP 91901637 A EP91901637 A EP 91901637A EP 91901637 A EP91901637 A EP 91901637A EP 0507948 A1 EP0507948 A1 EP 0507948A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bfgf
- arg
- asp
- antibody
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 139
- 238000000034 method Methods 0.000 claims abstract description 74
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 86
- 241000124008 Mammalia Species 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 14
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 14
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- 230000035755 proliferation Effects 0.000 claims description 13
- 210000004989 spleen cell Anatomy 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 230000007910 cell fusion Effects 0.000 claims description 4
- 210000003606 umbilical vein Anatomy 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000016784 immunoglobulin production Effects 0.000 claims description 2
- 238000009630 liquid culture Methods 0.000 claims description 2
- 210000003200 peritoneal cavity Anatomy 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000008569 process Effects 0.000 abstract description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 117
- 239000000243 solution Substances 0.000 description 55
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 239000000872 buffer Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000002609 medium Substances 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 102000003992 Peroxidases Human genes 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 18
- 239000008363 phosphate buffer Substances 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 15
- 108040007629 peroxidase activity proteins Proteins 0.000 description 15
- 239000012228 culture supernatant Substances 0.000 description 14
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 description 13
- 229920000669 heparin Polymers 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 230000003053 immunization Effects 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- 206010003445 Ascites Diseases 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229960002897 heparin Drugs 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 229920005654 Sephadex Polymers 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 108700020962 Peroxidase Proteins 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 210000003556 vascular endothelial cell Anatomy 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012847 fine chemical Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 4
- 229960001008 heparin sodium Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 240000003291 Armoracia rusticana Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- QVJOAJHDLCIURF-UHFFFAOYSA-N 1-[4-(2,5-dioxopyrrolidin-1-yl)oxybutan-2-yl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C)CCON1C(=O)CCC1=O QVJOAJHDLCIURF-UHFFFAOYSA-N 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 229960002163 hydrogen peroxide Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000001704 mesoblast Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- MJQHZNBUODTQTK-WKGBVCLCSA-N (2s,3r,4s,5r,6r)-2-[[(1s,3s,4s,5s,8r)-3-[(2s,3r,4s,5s,6r)-2-[[(1s,3r,4s,5s,8r)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5- Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H]2OC[C@@H]1O[C@@H](O[C@@H]1[C@H]([C@H](O[C@H]3[C@H]4OC[C@@H]3O[C@@H](O)[C@H]4O)O[C@H](CO)[C@@H]1O)O)[C@H]2O MJQHZNBUODTQTK-WKGBVCLCSA-N 0.000 description 1
- DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229920001890 Novodur Polymers 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 235000002098 Vicia faba var. major Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000007798 limiting dilution analysis Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to monoclonal antibodies which im uno-neutralize the biological activity of basic fibroblast growth factor (also briefly referred to as bFGF in the present specification) proteins and have high binding sensitivity with bFGF proteins, hybridomas secreting the same, their production and use thereof.
- basic fibroblast growth factor also briefly referred to as bFGF in the present specification
- bFGF is a basic polypeptide hormone having an affinity for heparin and a molecular weight of about 17,000 [D. Gospodarowicz, Nature 249, 123 (1974)]. It is now known that bFGF exhibits growth promoting action on almost all cells derived from mesoblast, and acts as a differentiating factor to a mesoblast system.
- bFGF induces the proliferation of nerve cells, the proliferation of vascular endothelial cells to cause angiogenesis, and the proliferation of cancer cells. Coupled with these functions, therefore, bFGF is involved in diseases such as tumors. Accordingly, a monoclonal antibody which inhibits the activity of bFGF would be useful as a therapeutic drugs for such diseases. However, this possibility has not been recognized till now. Further, as a means for diagnosing these diseases, the determination of blood bFGF concentrations is considered. It is however impossible to detect bFGF with great sensitivity by previously known methods. As discussed above bFGF is involved in diseases such as cancer, so that the inhibition of the growth promoting activity of bFGF to the cancer cells presents the possibility of use as a cancer therapy.
- bFGF itself may have application as a therapeutic drug for traumas and burns.
- the determination of fundamental information regarding bFGF is essential for the development of bFGF as a medicine.
- the diagnosis of the disease becomes possible by tracing the blood bFGF concentrations.
- bFGF is adsorbed by heparan sulfate existing among vascular endothelial cells, bFGF exists in blood only in trace amounts. Accordingly, there is a need in the art to develop a highly sensitive quantitative assay for measuring bFGF in the blood.
- the present invention provides: (1) a monoclonal antibody which has the following characteristics, it immuno-neutralizes the activity of a bFGF protein and has high binding sensitivity with the bFGF protein:
- rhbFGF mutein CS23 a mutein in which the cysteine residues at positions 70 and 88 of hbFGF are substituted for serine residues
- HUVE human unbilical vein endothelial
- a method for producing a cloned hybridoma which comprises fusing a spleen cell from a mammal and a homogenic or heterogenic lymphoid cell, said mammal being immunized with a mutein in which at least one cysteine residue of bFGF is substituted for a serine residue, and selecting the desired hybridoma, followed by cloning;
- (6) a method for detecting or measuring a bFGF protein, which comprises using the monoclonal antibody described in the above item (1) .
- FIG. 1 shows a cDNA sequence of human aFGF used in Reference Example 1
- Fig. 2 is a schematic representation showing the construction of plasmid pTB975 obtained in Reference Example 1;
- Figs. 3 to 5 show elution patterns obtained in Reference Example 1;
- Fig. 6 is a graph showing the affinity of monoclonal antibody 3H3 of the present invention obtained in Example 4 for rhbFGF mutein CS23;
- Fig. 7 is a graph showing the human bFGF-neutralizing activity of monoclonal antibody 3H3 of the present invention obtained in Example 6;
- Figs. 8(a) and 8(b) are graphs showing the proliferation inhibition effect of monoclonal antibody 3H3 of the present invention obtained in Example 6 for HUVE cells, in which Fig. 8(a) shows the results of cultivation for 3 days and Fig. 8(b) shows the results of cultivation for 5 days;
- Fig. 9 is a graph showing the relationship between the concentration and the absorbance of hbFGF, obtained in Example 9;
- Fig. 10(1) and 10(2) are graphs showing the influence of heparin in a hbFGF determination system, obtained in Example 10, in which Fig. 10(1) shows the results when MAbl2 is fixed, and Fig. 10(2) shows the results when a 50-50 mixture of MAb52 and MAb98 is fixed;
- Fig. 11(1) and 11(2) are graphs showing the reaction in a hbFGF determination system, obtained in Example 11, in which Fig. 11(1) shows the results when MAbl2 is solidified, and Fig. 11(2) shows the results when a 50-50 mixture of MAb52 and MAb98 is fixed;
- Fig. 12 is a graph showing the anti-tumor effect of an antibody of the present invention, obtained in Example 13;
- Fig. 13 is a schematic representation showing the construction of plasmid pTBlOOO obtained in Reference Example 2.
- the bFGF proteins of the present invention include bFGFs and muteins in which at least one cysteine residue of bFGF is substituted for a serine residue and which have bFGF activity.
- polypeptides containing the amino acid sequence represented by formula (I) there are preferably used polypeptides containing the amino acid sequence represented by formula (I) :
- the bFGFs of the present invention include bFGFs derived from mammals.
- the mammals include humans, monkeys, pigs, bovines, sheep and horses.
- the bFGFs also include bFGFs extracted from various organs existence of which is already clarified, such as brains and pituitary glands.
- the bFGF proteins may be produced by recombinant DNA techniques.
- amino acid sequences of the bFGFs include the amino acid sequence represented by formula (II):
- human bFGF is preferable.
- the human bFGF has the amino acid sequence in which X is Thr and Y is Ser in the above formula (II).
- the muteins in which at least one cysteine residue of the above bFGF is substituted for a serine residue include, for example, the muteins described in Seno et al., Biophys. Res. Commun. 151, 701 (1988) and European Patent Publication No. 281,822.
- rhbFGF mutein CS23 recombinant human bFGF mutein CS23 in which each of the cysteine residues at positions 70 and 88 of the human bFGF is substituted for a serine residue.
- Met is numbered as the first.
- examples of the human bFGF include bFGF produced by the methods described, for example, in FEBS Letters 213, 189 (1987), Biophys. Res. Commun. 146, 470 (1987) and European Patent Publication No. 237,966.
- mammals are immunized with the bFGF proteins or protein conjugates
- experimental animals such as sheep, goat, rabbits, guinea pigs, rats and mice, as the mammals to be immunized.
- rats or mice it is preferred to use rats or mice for immunization.
- mice When mice are immunized, for example, they can be immunized by any of the subcutaneous, intraperitoneal, intravenous, intramuscular and intracutaneous routes. However, subcutaneous, intraperitoneal and intravenous injections are preferably used. In particular, subcutaneous injection is preferable.
- the immunizing interval and the immunizing dose are widely variable, and various methods are available. For example, methods in which immunization is carried out about 2 to 6 times at intervals of 2 weeks and spleen cells are removed after about 1 to 5 days, preferably about 2 to 4 days from the final immunization are frequently used.
- the immunizing dose it is preferred to use about 0.1 ⁇ g or more, preferably about 10 to 300 ⁇ g of the peptide per one immunization of a mouse. Further, it is desirable to carry out the fusion process using the spleen cells after confirmation of an increase in antibody titer in blood by collecting a portion of blood and measuring the antibody titer before removal of the spleens.
- lymphoid cells are then fused with lymphoid cells.
- lymphoid cell strains such as suitable myeloma cells [for example, P3-X-63-Ag"8UI (Ichimori et al., J. Immun. Method 80, 55 (1985))] of the same kind or a different kind (preferably the same kind) having markers such as hypoxanthine-guanine-phosphoribosyl-transferase deficient (HGPRT-) and thymidine kinase deficient (TK ⁇ ).
- suitable myeloma cells for example, P3-X-63-Ag"8UI (Ichimori et al., J. Immun. Method 80, 55 (1985)
- suitable myeloma cells for example, P3-X-63-Ag"8UI (Ichimori et al., J. Immun. Method 80, 55 (1985)
- HGPRT- hypoxanthine-guanine-phosphoribosyl
- the fused cells are produced in accordance with the method of Kohler and Milstein [Nature 256, 495 (1975)].
- myeloma cells and spleen cells in a ratio of about 1:5 are suspended in a medium prepared by mixing Iskov medium and Ham F-12 medium in a 1:1 ratio (hereinafter referred to as IH medium), and a fusion accelerator such as Sendai virus or polyethylene glycol (PEG) is added thereto.
- a fusion accelerator such as Sendai virus or polyethylene glycol (PEG)
- PEG polyethylene glycol
- DMSO dimethyl sulfoxide
- the polymerization degree of PEG is usually about 1,000 to 6,000, the fusion time is about 0.5 to 30 minutes, and the concentration of the suspension is about 10 to 80%.
- the fusion is carried out efficiently by using PEG 6,000 in a concentration of about 35 to 55% for about 4 to 10 minutes.
- the fused cells can be selectively proliferated using hypoxanthine-aminopterin-thy idine medium (HAT medium) [Nature, 256, 495 (1975)].
- HAT medium hypoxanthine-aminopterin-thy idine medium
- the culture supernatant of the proliferated cells is then screened for the production of the desired antibody. Screening of the antibody titer can be carried out in the following manner. First, the presence or absence of the antibody production by peptide immunization is examined by radio im unoassays (RIAs) or enzyme immunoassays (EIAs). For these methods, various modified methods are also available. As a preferred example of the assays, a method using the EIA is described below.
- a rabbit anti-mouse immunoglobulin antibody is coupled with a carrier such as cellulose beads according to conventional methods, and then a culture supernatant or mouse serum to be assayed is added thereto, followed by reaction at a constant temperature (about 4 to 40 C, the same applied hereinafter) for a definite time.
- a constant temperature about 4 to 40 C, the same applied hereinafter
- an enzyme-labeled peptide a peptide is coupled with an enzyme according to conventional methods, followed by purification
- reaction at a constant temperature for a specified time After the reaction product is thoroughly washed, an enzyme substrate is added thereto, followed by reaction at a constant temperature for a specified time. Then, the absorbance or fluorescence of the color-produced product is measured.
- the screening of the neutralizing activity to the bFGF proteins can be carried out in the following manner.
- the neutralizing activity can be examined using cells whose proliferation is induced by the bFGF proteins.
- cells there can be used vascular endothelial cells, fibroblasts, nerve cells and the like. It is however desirable to know whether or not the additional effect of the bFGF proteins is inhibited by measuring the number of cells, using the vascular endothelial cells begin a new paragraph.
- Methods for measuring the number of cells include a method for measuring directly the number of cells, a method for determining radioactivity by using tritium thymidine and a method for measuring colorimetrically using (4,5-dimethyl- 2-thiazoly)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (MTT method).
- MTT method 4,5-dimethyl- 2-thiazoly-2,5-diphenyl-2H-tetrazolium bromide
- the bFGF protein and the culture supernatant to be assayed are added thereto, followed by cultivation at a constant temperature (37 C) at a low concentration of oxygen (about 7% is preferable) for a definite time. Then, the culture solution are replaced by a medium containing MTT, and cultivation is further continued, whereby MTT is reduced to a formazan, a colorimetric material, in intracellular endogenous mitochondria.
- the concentration of the formazan is made even, the absorbance at 590 nm is measured.
- the proliferative property of cells correlates with the absorbance. Hence, if the solution containing the hybridoma supernatant is decreased in absorbance compared with a solution not containing the hybridoma supernatant, the antibody contained in the supernatant can be said to have bFGF neutralizing activity.
- the cells in wells which proliferate in a selective medium and which produce antibodies with immuno-neutralizing activity to the peptide used for immunization be cloned by a limiting dilution analysis.
- the supernatant of the cloned cells is similarly screened, and the selected cells which show a high antibody titer are proliferated, whereby monoclonal antibody- producing hybridoma clones showing the reactivity with the immunized peptide can be obtained.
- the hybridoma cells thus cloned are proliferated in a liquid medium.
- the hybridoma cells are cultivated in the liquid medium such as a medium prepared by adding about 0.1-40% bovine serum to RPMI-1640 [G. E. Moore et al., J. Am. Med. Assoc. 199, 549 (1967)], for about 2 to 10 days, preferably for 3 to 5 days, whereby the monoclonal antibody can be obtained from the culture solution.
- the antibody can further be obtained by intraperitoneally inoculating mammals with the hybridoma cells, thereby proliferating the cells and then collecting the ascites.
- a mouse for example, about 1 X 10 4 to 1 X 10 7 , preferably 5 X 10 5 to 2 X 10 6 of the hybridoma cells are intraperitoneally inoculated into a mouse such as BALB/c preliminarily inoculated with mineral oil and the like, and the ascites is collected after about 7 to 20 days, preferably after about 10 to 14 days.
- the monoclonal antibody formed and accumulated in the ascites can be easily isolated as pure immunoglobulin by ammonium sulfate fractionation, DEAE-cellulose column chromatography or the like.
- the monoclonal antibodies of the present invention have high binding sensitivity not only with the immunogen peptides, but also with the bFGF proteins, and further exhibit the neutralizing activity to the bFGF proteins. As a result of this high binding sensitivity, the monoclonal antibodies of the present invention are very useful as reagents for assaying the bFGF proteins and for purifying the bFGF proteins.
- the bFGF proteins can be assayed to 20 pg/ml by the assays using the monoclonal antibodies of the present invention.
- the ability to assay such an extremely small amount of bFGF ii vivo is an important development in the art.
- diseases induced by overproduction of bFGF tumors are mentioned.
- cancer cells proliferate directly by bFGF and the case that vascular endothelial cells react with bFGF produced from the tumors to proliferate and induce new formed blood vessels which supply nutritive substances to the tumors, which results in enlarged tumor masses.
- these diseases can be anticipated by measuring the amount of the bFGF overproduced. Since bFGF easily adheres to the inner walls of blood vessels, it is therefore important to have a detecting or determining assay method as sensitive as possible.
- bFGF is considered to improve the symptoms thereof effectively.
- the monoclonal antibodies of the present invention can be used as means for tracing the amount of the mutein m. vivo, because the monoclonal antibodies also have high binding sensitivity with the mutein in which at least one cysteine residue is substituted for a serine residue.
- the monoclonal antibodies of the present invention inactivate the bFGF in vivo and exhibit antitumor activity, because of their strong immuno-neutralizing activity.
- the monoclonal antibodies are administered in an amount of about 100 ⁇ g/kg to 10 mg/kg. These monoclonal antibodies are also effective for treatment of enlarged tumors following angiogenesis.
- Examples of the methods for detecting or assaying the bFGF proteins include an immunoassay for assaying the bFGF proteins by using an anti-bFGF antibody supported on a carrier and a conjugate obtained by combining an anti-bFGF antibody directly with a labeling agent, the anti-bFGF antibody differing from the antibody held on the carrier in an antigen determinant.
- the carriers on which the antibody is held in the above-mentioned assay include, for example, gel particles such as agarose gels [for example, Sepharose 4B and Sepharose 6B (Pharmacia Fine Chemical, Sweden)], dextran gels [for example, Sephadex G-75, Sephadex G-100 and Sephadex G-200 (Pharmacia Fine Chemical, Sweden) ] and polyacrylamide gels [for example, Biogel P-30, Biogel P-60 and Biogel P-100 (Bio RAD Laboratories, U.S.A.)]; cellulose particles such as Avicel (Asahi Chemical Industry, Japan) and ion exchange cellulose (for example, diethylaminoethyl cellulose and carboxymethyl cellulose); physical adsorbents such as glass (for example, glass balls, glass rods, aminoalkyl glass balls and aminoalkyl glass rods), silicone pieces, styrenic resins (for example, polystyrene balls and polystyrene
- the antibody In order to couple the antibody onto the carrier. methods known in the art are applied. Examples of such methods include the cyanogen bromide method and the glutaraldehyde method which are described in Metabolism, j3, 696 (1971). As a simpler method, the antibody may be physically adsorbed on the surface of the carrier.
- the labeling agents with which the antibodies are combined include radioisotopes, enzymes, fluorescent substances and luminous substances. However, it is preferred to use the enzymes.
- the enzymes which are preferably stable and high in specific activity, there can be used peroxidases, alkaline phosphatases, 3-D- galactosidases, glucose oxidases and the like.
- peroxidases is preferably used.
- Peroxidases of various origins can be used. Examples of such peroxidases include peroxidases obtained from horseradishes, pineapples, figs, sweet potatoes, broad beans and cone.
- horseradish peroxidase (HRP) extracted from horseradishes is preferable.
- the thiol group of Fab 1 as the antibody molecule is utilized, and peroxidase into which a maleimide group is preliminarily introduced is conveniently used.
- a maleimide group When a maleimide group is introduced into peroxidase, it can be introduced through an amino group of peroxidase.
- N-succinimidyl-maleimide-carboxylate derivatives can be used.
- N-( ⁇ -maleimidobutyloxy)succinimide (hereinafter also briefly referred to as GMBS) is preferably used. A certain group may therefore intervene between the maleimide group and perxidase.
- GMBS is reacted with peroxidase in a buffer solution having a pH of 6 to 8 at about 10 to 50°C for about 10 minutes to about 24 hours.
- the buffer solutions include, for example, 0.1 M phosphate buffer (pH 7.0).
- the maleimidated peroxidase thus obtained can be purified, for example, by gel chromatography. Examples of carriers used in the gel chromatography include Sephadex G-25 (Pharmacia Fine Chemical, Sweden) and Biogel P-2 (Bio RAD Laboratories, U.S.A. ) .
- the maleimidated peroxidase can be reacted with the antibody molecule in a buffer solution at about 0 to 40 C for about 1 to 48 hours.
- the buffer solutions include, for example, 0.1 M phosphate buffer (pH 6.0) containing 5 mM sodium ethylenediaminetetraacetate.
- the peroxidase-labeled antibody thus obtained can be purified, for example, by gel chromatography. Examples of carriers used in the gel chromatography include Sephadex G-25 (Pharmacia Fine Chemical, Sweden) and Biogel P-2 (Bio RAD Laboratories, U.S.A. ) .
- a thiol group may be introduced into peroxidase to allow it to react with the maleimidated antibody molecule.
- Enzymes other than peroxidases can be directly combined with the antibodies similarly to the methods of combining peroxidases, and known methods which achieve such combining include body fluids or, for example, the glutaraldehyde method, the periodic acid method and the water-soluble carbodiimide method.
- Test samples used in the assay system of the present invention include humors such as urine, serum, plasma and cerebrospinal fluid, extracts of animal cells, and culture supernatants thereof.
- test sample containing the bFGF protein to be assayed is added to the antibody held on a carrier to conduct antigen-antibody reaction, and then the conjugate of the peroxidase with the anti-bFGF protein antibody obtained above is added thereto, followed by reaction.
- the purified antibody of the present invention is coupled with a suitable carrier such as activated agarose gel beads according to conventional methods, and packed in a column. Then, a sample containing the crude bFGF protein, such as a culture supernatant or disrupted cells, is loaded onto the antibody affinity column to allow the sample to be adsorbed thereby, followed by washing. Then, elution is carried out with a chaotropic reagent such as potassium thiocyanate (KSCN) or under such acescent conditions that the bFGF is not inactivated.
- KSCN potassium thiocyanate
- the antibody column can be prepared by coupling the monoclonal antibody of the present invention, which is, for example, purified from ascites or other humors inoculated with the hybridoma cells, with an appropriate carrier.
- any carrier may be used as long as the bFGF protein is specifically efficiently adsorbed thereby after coupling and suitable elution is thereafter possible.
- carriers include agarose gels, cellulose and acrylamide polymers.
- polyacrylamide gel beads in which primary amines of the proteins are activated so as to be easily combinable such as Affi-Gel 10 (Bio RAD), are conveniently used according to the following method.
- the antibody is reacted with Affi-Gel 10 in a buffer solution such as a bicarbonate solution having a concentration of about 0.001 to 1 M, preferably about 0.1 M.
- the reaction is conducted at about 0 to 20°C at a broad pH range for about 10 minutes to about 24 hours, preferably at about 4 C at a pH of about 3 to 10 for about 4 hours.
- the larger amount of antibody is mixed with Affi-Gel 10
- the larger amount of antibody becomes combined therewith, within the range up to about 50 mg of antibody per 1 ml of Affi-Gel 10.
- the antibody may therefore be mixed with Affi-Gel 10 in any ratio within this range.
- about 10 to 30 mg of the antibody is conveniently used, considering the combining efficiency and the purification efficiency in affinity chromatography.
- the antibody-carrier combined material thus formed is thoroughly washed with the buffer solution used for the reaction. Then, residual unreacted active groups are blocked by allowing the washed material to stand for several days, by adding a compound containing a primary amine such as ethanolamine-hydrochloric acid or glycine thereto to a final concentration of about 0.05 to 0.10 M, followed by reaction at about 4°C for about 1 to 4 hours, or by reacting a protein such as 1 to 5% bovine serum albumin (BSA) therewith at 4°C overnight.
- BSA bovine serum albumin
- the bFGF protein-containing sample is dissolved in a buffer solution having a pH around neutrality such as phosphate buffer or Tris-hydrochloric acid buffer, followed by adsorption by the antibody column. Then, the column is washed with the same buffer, and then the bFGF protein is 5 eluted.
- a buffer solution having a pH around neutrality such as phosphate buffer or Tris-hydrochloric acid buffer
- the column is washed with the same buffer, and then the bFGF protein is 5 eluted.
- the following solutions are commonly used: weakly acidic solutions such as acetic acid solutions, solutions containing polyethylene glycol, solutions containing peptides more easily combinable with the antibody than the sample, high concentration salt solutions and their
- the substantially pure bFGF protein substantially free from pyrogens and endotoxins can be obtained.
- the substantially pure bFGF protein of the present invention contains the bFGF protein in a concentration of 90% (w/w) or more, and preferably in a concentration of 95% (w/w) or 0 more.
- the monoclonal antibodies of the present invention immuno-neutralize the biological activity of the bFGF proteins at low concentrations and have high binding sensitivity with the bFGF proteins, so that they can be used 5 as therapeutic drugs for treatment of diseases such as cancer, and as reagents for assaying the bFGF proteins.
- Mouse 3H3 cells obtained in Example 2-(4) described below was deposited with the Institute for Fermentation, Osaka, Japan (IFO) under the accession number IFO 50216 on November 10, 1989. The above cells were also deposited with the Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, Japan (FRI) under the accession number FERM BP- 2658 on November 14, 1989.
- Anti-bFGF monoclonal antibodies MAbl2, MAb52 and MAb98 described in the following Examples can be produced by the methods described in Hybridoma, 8, 209-221 (1989) and
- the recognition site of MAbl2 is included in the amino acid sequence of from position 1 (the N-terminus) to position 9 of bFGF, and the recognition sites of MAb52 and MAb98 are included in the amino acid sequence of from position 14 to position 40 of bFGF.
- Recombinant human aFGF which was produced by the methods described in Reference Example 1 was used.
- rhbFGF Recombinant human bFGF
- Escherichia coli MM294(DE3)/LysS,pTB762 which is produced in Reference Example 1 was deposited with IFO under the accession number IFO 14936 on September 12, 1989. This transformant was also deposited with FRI under the accession number FERM BP-2599 on September 20, 1989.
- pET3c As a vector DNA, there was used pET3c [F. W. Studier et al., J. Mol. Biol., 189, 113-130 (1986)] carrying a Z$10 promoter for a T7 phage.
- pET3c was cleaved with Ndel and the termini thereof were made flush by treatment with large fragment. Then, an Ncol linker, 5*-CCATGG-3' , was ligated thereto with T4 DNA ligase. The resulting plasmid was cleaved with Ncol, and the cleaved ites were made flush with DNA polymerase large fragments, followed by cleavage with BamHI to remove the sequence of S10.
- This strain was cultivated in a medium containing 35 ⁇ g/ml of ampicillin and 10 ⁇ g/ml of chloramphenicol. When the turbidity reached 170 Kletts, isopropyl-6-D- thiogalactoside (IPTG) was added thereto to a final concentration of 0.5 mM, and cultivation was further continued for 3 hours. The cells were collected by centrifugation and washed with ice-cooled PBS. Then, the cells were collected again and stored at -20°C until their use.
- IPTG isopropyl-6-D- thiogalactoside
- This supernatant was mixed with 200 ml of an ice-cooled solution [20 mM Tris-HCl (pH 7.4), 1 mM EDTA], and the mixture was loaded onto a heparin Sepharose column (2.5 cm diameter X 4 cm) equilibrated with a buffer [20 mM Tris-HCl (pH 7.4), 1 mM EDTA].
- the column was washed with 150 ml of a solution [20 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1.5 M NaCl], and then the protein was eluted with an eluting solution [20 mM Tris-HCl (pH7.4), 1 mM EDTA, 1.5 M NaCl].
- the eluate was fractionated into 6 ml portions and 0D fln was monitored to collect the second peak fraction (8th to 11th, the total amount: 24 ml) (Fig. 3). Twenty-two ml of the eluate was mixed with an equal volume of solution 20 mM Tris-HCl (pH 7.4), 1 mM EDTA, 2 M (NH. )_S0.), and the mixture was loaded onto a phenyl
- Sepharose column (2.5 cm diameter X 8 cm) equilibrated with a buffer [20 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 M (NH 4 ) 2 S0 4 ] (flow rate: 0.5 ml/min).
- the column was washed with 20 ml of the same buffer, and eluted with a linear gradient of 0 to 1 M ammonium sulfate (flow rate: 0.5 ml/min, gradient time: 200 minutes).
- the eluted fractions 40 to 55 (Fig. 4) were collected as purified human aFGF.
- a 1.2 mg/ml solution of the purified human aFGF was mixed with 0.25 ml of 0.1% trifluoroacetic acid (TFA), and the mixture was applied to a reverse-phase C4 column (VYDAC) .
- the column was eluted with a linear gradient of 0 to 90% acetonitrile in 0.1% TFA to examine an elution pattern.
- the flow rate was 1 ml/min and the gradient time was 60 minutes (Fig. 5) .
- the activity of the human aFGF was determined by
- Plasmid pTB762 obtainable from E. coli MM294(DE3)/
- Lys,pTB672 (IFO 14936, FERM BP-2599), and described in
- Mouse BALB/c3T3 clone A31 cells [T. akunaga et al. Science, 209, 505-507 (1980)] were seeded on a 6 cm diameter dish for tissue culture having DMEM medium
- Each of these transformed cells showed the form of a malignant cell gland and formed colonies on a soft agar plate.
- mice female, 8 weeks old were intraperitoneally injected with 50 ⁇ g of antigen rhbFGF mutein CS23 (a mutein in which each of Cys residues at positions 70 and 88 of human bFGF were substituted for a Ser residue) which was dissolved in Freund's complete adjuvant (Difco) . Two weeks later, the mice were intraperitoneally given again 50 ⁇ g of antigen rhbFGF mutein CS23 dissolved in 0.4 ml of Freund's complete adjuvant.
- antigen rhbFGF mutein CS23 a mutein in which each of Cys residues at positions 70 and 88 of human bFGF were substituted for a Ser residue
- mice were additionally immunized with 50 ⁇ g of antigen rhbFGF mutein CS23 dissolved in 0.4 ml of Freund's incomplete adjuvant.
- 50 ⁇ g of rhbFGF mutein CS23 dissolved in physiological saline was inoculated into the caudal veins of the mice.
- Mouse myeloma cells SP2/0-AG14 (ATCC No. CRL 1581) were subcultured in DMEM medium containing 10% fetal calf serum under an atmosphere of 5% carbon dioxide and 95% air.
- PEG 7 (2 X 10 cells) were mixed with the immunized lymphocytes g (1.5 X 10 cells) obtained by the above method, and the mixture was centrifuged. Then, 1 ml of a 45% solution of polyethylene glycol 6000 (hereinafter referred to as PEG
- IH medium containing 20% calf serum
- HAT 1 X 10 -4 M hepoxanthine, 4 X 10-7 M am opterin, 1.6 X 10 —5 M thymidine
- HAT medium 1 X 10 -4 M hepoxanthine, 4 X 10-7 M am opterin, 1.6 X 10 —5 M thymidine
- HAT medium 1 X 10 -4 M hepoxanthine, 4 X 10-7 M am opterin, 1.6 X 10 —5 M thymidine
- a fixing buffer [0.1 M sodium hydrogencarbonate (pH 9.6), 0.02% sodium azide] containing 200 ng/ml of rhbFGF mutein CS23 was added in an amount of 100 ⁇ l/well to a 96- well polystyrene microtiter plate (Nunc) .
- the microtiter plate was washed with a rinsing liquid (0.05% Tween 20, physiological phosphate buffer), and then 100 ⁇ l of the combined solution of 50 ⁇ l of the culture supernatant and 50 ⁇ l of a buffer for dilution (0.05 M Tris-HCl buffer pH 8.01, 1 mM magnesium chloride, 0.15 M sodium chloride, 0.05% Tween 20, 0.02% sodium azide, 0.3% gelatin) was added to the microtiter plate. After 2 hours, the culture supernatant was washed with a rinsing liquid, followed by addition of the alkaline phosphatase-labeled anti-mouse IgG goat antibody (Bio RAD) as the second antibody.
- a rinsing liquid 0.05% Tween 20, physiological phosphate buffer
- a buffer for dilution 0.05 M Tris-HCl buffer pH 8.01, 1 mM magnesium chloride, 0.15 M sodium chloride, 0.05% Tween 20,
- the second antibody was washed with a rinsing liquid, and then coloring reaction was conducted by adding a reaction substrate (ELISA method) .
- ELISA method reaction substrate
- GIT culture solution containing various concentrations of hybridoma culture supernatants, 4 ng/ml rhbFGF and 2.5% fetal calf serum was added in an amount of 100 ⁇ l/well, and cultivation was conducted at 37°C under an atmosphere of 5% C0 and 7% 0 choir for 3 days. After 3 days, the culture solution was removed, and then GIT culture solution containing 1 mg/ml MTT (4,5-dimethyl-2-thiazolyl- 2,5-diphenyl-2H-tetrazolium bromide) and 2.5% fetal calf serum was added in an amount of 100 ⁇ l/well.
- MTT 4,5-dimethyl-2-thiazolyl- 2,5-diphenyl-2H-tetrazolium bromide
- Hybrid Cells The cells in this well were spread to 0.5 cell per well on a 96-well microtiter plate on which mouse thymocytes had preliminarily been spread as vegetative cells, and cloning was carried out. As a result, hybridoma mouse 3H3 cells (IFO 50216, FERM BP-2658) were obtained. The cloned cells were stored in liquid nitrogen, adding dimethyl sulfoxide (DMSO) to IH medium containing 20% calf serum to a concentration of 10%. - 33 -
- DMSO dimethyl sulfoxide
- Example 2-(3) The culture supernatant of 3H3 cells obtained in Example 2-(3) were reacted with various immunoglobulin samples by a subclass detecting kit (Bio RAD) . The results are shown in Table 1.
- the IgG amount of the samples was determined according to the method described in Example 2-(2) in the following manner. Various dilutions of mouse IgG whose concentration was known and the 3H3 antibody were fixed on a 96-well polystyrene microtiter plate with a fixing buffer. After 2 hours, the alkaline phosphatase- labeled anti-mouse IgG goat antibody (Bio RAD) was added thereto. After 2 hours, coloring reaction was conducted by adding a reaction substrate (ELISA method). With respect to mouse IgG, a determination curve was drawn, and the IgG amount of the samples was determined based on this curve, whereby a 60 ⁇ g/ml solution of the 3H3 antibody was prepared.
- Fig. 6 shows the results of the antibody titer to rhbFGF mutein CS23 measured for the monoclonal antibody thus purified, according to the method described in Example 2- (2).
- One ⁇ g/ml of the rabbit anti-bFGF polyclonal antibody was fixed and rhbFGF mutein CS23 was added thereto.
- 1 ⁇ g/ml of the 3H3 antibody was added and 1 ⁇ g/ml of the alkaline phosphatase-labeled anti-mouse IgG goat antibody was further added thereto.
- rhbFGF mutein CS23 could be detected up to 3 ng/ml.
- the antibody was purified from ascites.
- the mouse 3H3 cell strain was injected into the mice (Balb/c) .
- IgG was purified from the ascites according to conventional methods. Namely, 5 ml of the ascites was subjected to salt precipitation using a 45% saturated solution of ammonium sulfate, and the precipitate was dissolved in borate buffer (BBS, pH 8.5) containing 0.15 M NaCl, followed by dialysis against BBS at 4°C for 20 hours.
- BBS borate buffer
- the antigen recognition site of the 3H3 antibody whose antibody titer was measured in Example 4 was examined by competitive binding inhibition experiments.
- competitive substances there were used human aFGF, rhbFGF, rhbFGF mutein CS23, synthetic peptides pep 1: Pro-Ala-Leu-Pro-Glu- Asp-Gly-Gly-Ser-Tyr [the peptide in which Tyr was added to the C-terminus of N-terminal amino acids 2 to 10 of human bFGF, Regulatory Peptides, 10, 309-317 (1985)] and pep 2: Leu-Pro-Met-Ser-Ala- Lys-Ser (corresponding to amino acids 141 to 147, refer to European Patent Publication No.
- the synthetic peptides, heparin sodium, human aFGF, rhbFGF and rhbFGF mutein CS23 were diluted with the buffer for dilution used in Example 2-(2) to a concentration of 100 ⁇ g/ml.
- the synthetic peptides, heparin sodium, human aFGF, rhbFGF and rhbFGF mutein CS23 were used as the competitive substances, 100 ng/ml of the 3H3 antibody and the competitive substance were suspended, and the suspension was maintained at 37°C for 60 minutes.
- the recognition site of the 3H3 antibody is considered to be the peptide of 10th to 141st amino acids of human bFGF molecule and binding site of human bFGF to human bFGF receptor or its adjacent site, other than the heparin combining site, or a region adjacent thereto.
- Example 6 (Examination of Immuno-Neutralizing Action)
- the human bFGF-immunoneutralizing activity against rhbFGF was studied by the MTT method of Example 2-(3) (Fig. 7). Namely, the activity was assayed by 3-day proliferation in the presence of 2 ng/ml of bFGF of the human umbilical vein endothelial (HUVE) cell.
- the proliferation inhibitory effect is shown by the absorbance at OD-590 nm in case of adding the monoclonal antibodies where the value is estimated as 100% both in the presence of the bFGF and in the absence of the monoclonal antibody. Referring to Fig.
- the assay was further changed to study the proliferation inhibition effect of the HUVE cells.
- the HUVE cells were seeded on a 24-well Linbro plate in an amount of 1 X 10 cells/well (the culture conditions were37he same as with Example 2-(3)).
- 2 ng/ml of the bFGF and the 3H3 antibody were added thereto. followed by cultivation for 3 days and for 5 days.
- the number of cells was measured by using a Coulter counter (Coulter Electronics, Inc.) for each case.
- Figs. 8(A) shows the results when cultivation was carried out for 3 days
- Fig. 8(B) shows the results when cultivation was carried out for 5 days.
- the number of cells when the 3H3 antibody was added was expressed in percentage, taking the number of cells when the bFGF was added and the 3H3 antibody was not added as 100%.
- - • - and - jp - indicate the effect of the 3H3 antibody in the presence of 2 ng/ml of the bFGF and in the absence of the bFGF, respectively.
- the IC50 value of the proliferation hindrance shows 13.2 and 7.6 ng/ml in Fig. 8(A) and Fig. 8(B), respectively.
- the 3H3 antibody did not affect the number of cells in the absence of the bFGF. It is clear from the above data that the 3H3 antibody has strong immuno-neutralizing action to the biological activity of the bFGF.
- Example 7 (Preparation of Horseradish Peroxidase-Labeled 3H3 Antibody)
- the purified 3H3 antibody (7 mg/ml) was dialyzed against 0.1 M acetate buffer (pH 4.5) containing 0.1 M NaCl at 4 C for 20 hours, followed by addition of pepsin (0.1 mg) (Sigma, U.S.A.). Then, digestion was carried out at 37°C for 8 hours. The solution was adjusted to pH 8 with 1 M Tris to terminate the reaction. The resulting solution was placed on a column of Ultrogel AcA44 (IBF, France) and eluted with 0.02 M borate buffer (pH 8.0) containing 0.15 M NaCl to obtain F(ab') 2 .
- the solution containing F(ab') 2 was concentrated to 1 ml. Then, the concentrated solution was dialyzed against 0.1 M phosphate buffer (pH 6.0) at 4 C for 20 hours, and 0.1 ml of a solution [0.2 M mercaptoethyl- amine, 5 mM EDTA, 0.1 M phosphate buffer (pH 6.0)] was added, followed by reduction at 37°C for 90 minutes. The reaction solution was placed on a Sephadex G-25 fine column (1 cm diameter X 60 cm, Pharmacia Fine Chemical, Sweden) and eluted with an eluent [5 mM EDTA, 0.1 M phosphate buffer (pH 6.0)] to obtain an Fab' fraction.
- HRP horseradish peroxidase
- GMBS N-( ⁇ -maleimidobutyloxy)succinimide
- DMF N,N-dimethylformamide
- the solution of GMBS in DMF was added to the HRP solution, followed by stirring at 30 C for 60 minutes. Then, the resulting solution was placed on the Sephadex G-25 fine column (1.2 cm diameter X 60 cm) and eluted with 0.1 M phosphate buffer (pH 7.0) to obtain maleimide group- introduced HRP (maleimidated HRP).
- MAbl2 or a 50-50 mixture of MAb52 and MAb98 was diluted with 0.1 M carbonate buffer (pH 9.6) to a concentration of 10 ⁇ g/ml. The resulting solution was poured in an amount of
- Buffer B 0.02 M phosphate buffer (pH 7.0) containing 25% Blockace (blocking agent prepared from milk protein) (Dainippon Pharmaceutical), 0.15 M NaCl],
- Fig. 9 shows the relationship between the concentration of the hbFGF and the absorbance. Referring to Fig. 9, - o - and - • - indicate the relationship between
- the amount of the bFGF in the test samples was assayed - 42 -
- rhbFGF Recombinant human bFGF
- Buffer B 0.02 M phosphate buffer (pH 7.0) containing 25% Blockace, 0.15 M NaCl
- Buffer D used for dissolution of o-phenylenediamine [0.1 M citrate buffer (pH 5.5) containing 0.02% hydrogenperoxide and 0.005% thimerosal],
- Example 10 Influence of Heparin in hbFGF Assay System
- heparin was added to buffer B to a concentration of 0, 1, 10 or 100 ⁇ g/ml, when the standard hbFGF was diluted.
- the concentration of the hbFGF was assayed in the manner of Example 4-(l).
- Figs. 10(1) and 10(2) there were observed no considerable changes in the standard curves with the presence of heparin, as shown in Figs. 10(1) and 10(2).
- Fig. 10(1) indicates the results when MAbl2 was fixed
- Fig. 10(2) indicates the results when the 50-50 mixture of MAb52 and MAb98 was fixed.
- - • -, - o -, - ⁇ - and - ⁇ - indicate the results when heparin concentrations are 0, 1, 10 and 100 ⁇ g/ml, respectively.
- Example 11 Reactivity of Acid-Modified hbFGF in hbFGF Assay
- Example 11(2) indicates the results when the 50-50 mixture of MAb52 and MAb98 was solidified. Further in each figure, - o -, - • -, - ⁇ - and - - indicate the results when the hbFGF was incubated at pH 4 for 0, 1, 3 and 10 minutes, respectively. Figs. 11(1) and 11(2) show that the hbFGF modified at pH 4 is reduced in reactivity to about 1% by incubation for 10 minutes in each assay system.
- the assay systems of Example 9 are assay systems by which only the native hbFGF can be assayed.
- Example 12 (Assay of bFGF in Various Cells)
- A375 human melanoma
- A431 human squamous cell carcinoma
- A549 human lung cancer
- SK-Hepl human hepatic cancer
- Table 3 A shows the results when MAbl2 was fixed, and B shows the results when the 50-50 mixture of MAb52 and MAb98 was fixed. Table 3 Amount of bFGF in Cell
- the K1000-F1 cells obtained in Reference Example 2 were - 46 -
- Fig. 12 (major axis) X (minor axis) 2] was calculated. The results are shown in Fig. 12. Referring to Fig. 12, - • -, - Q - and - J - indicate the results for an untreated control group, a nonimmune mouse IgG-given group and a 3H3 antibody-given group, respectively.
- the 3H3 antibody exhibited antitumor effect against the KlOOO tumor (14 days after implantation, the 3H3 antibody-given group is decreased in tumor volume to 34% of that of the untreated control group) . The antitumor effect of nonimmune mouse IgG was not observed.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP338369/89 | 1989-12-28 | ||
JP33836989 | 1989-12-28 | ||
JP169707/90 | 1990-06-29 | ||
JP16970790 | 1990-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0507948A1 true EP0507948A1 (de) | 1992-10-14 |
Family
ID=26492964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91901637A Withdrawn EP0507948A1 (de) | 1989-12-28 | 1990-12-27 | Monoklonaler antikörper, hybridome, ihre herstellung und verwendung |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0507948A1 (de) |
JP (1) | JPH05503842A (de) |
CA (1) | CA2069872A1 (de) |
WO (1) | WO1991009875A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104231079A (zh) * | 2014-09-12 | 2014-12-24 | 暨南大学 | 一种靶向bFGF高亲和力受体结合位点的抗体及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60145088A (ja) | 1984-01-07 | 1985-07-31 | Agency Of Ind Science & Technol | 動物細胞培養用組成物の製造法 |
US4935352A (en) | 1985-10-21 | 1990-06-19 | Takeda Chemical Industries, Ltd. | Expression vector for animal cell line and use thereof |
DK122687A (da) | 1986-03-14 | 1987-09-15 | Takeda Chemical Industries Ltd | Polypeptid, dna og anvendelse deraf |
JP2526965B2 (ja) | 1987-02-24 | 1996-08-21 | 武田薬品工業株式会社 | ムテイン,dnaおよびその用途 |
DE3852561T2 (de) | 1987-03-03 | 1995-07-13 | Takeda Chemical Industries, Ltd., Osaka | Monoklonaler Antikörper, Hybridomen, ihre Herstellung und ihre Verwendung. |
JP2506944B2 (ja) | 1988-06-13 | 1996-06-12 | 松下電器産業株式会社 | 波長可変レ―ザ装置 |
-
1990
- 1990-12-27 WO PCT/JP1990/001726 patent/WO1991009875A1/en not_active Application Discontinuation
- 1990-12-27 CA CA002069872A patent/CA2069872A1/en not_active Abandoned
- 1990-12-27 JP JP3501880A patent/JPH05503842A/ja active Pending
- 1990-12-27 EP EP91901637A patent/EP0507948A1/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9109875A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1991009875A1 (en) | 1991-07-11 |
JPH05503842A (ja) | 1993-06-24 |
CA2069872A1 (en) | 1991-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5712100A (en) | Antibodies to peptides having NGF-like activity, and use thereof | |
US5217896A (en) | Monoclonal antibodies recognizing parathyroid hormone-like protein | |
US6001580A (en) | Method for assaying ERK2 map kinase | |
JPH0772200B2 (ja) | 人フィブリンiiのnh2 末端フラグメントに対するモノクロナール抗体 | |
US5571895A (en) | Modified GAF polypeptides | |
EP0522159B1 (de) | Antikörper gegen hypophysäre adenylatzyklase aktivierende peptid-pacap, hybridome und bestimmung von pacap | |
US4882275A (en) | Method of purifying endothelial cell growth factors using immobilized heparin | |
CA2089212C (en) | Antibodies to human gastrin-releasing peptide precusor and use thereof | |
EP0418590B1 (de) | Antikörper, ihre Herstellung und Verwendung | |
US7662380B2 (en) | ZAQ ligand-1 antibodies and uses thereof | |
US6183971B1 (en) | Human betacellulin-specific antibodies and uses thereof | |
US5437995A (en) | Monoclonal antibody against an acidic FGF protein and hybridoma for its production | |
JP3057292B2 (ja) | モノクローナル抗体、ハイブリドーマ、それらの製造法および用途 | |
Brandt et al. | Functional and molecular characterization of a monoclonal antibody against human interleukin 2 | |
EP0507948A1 (de) | Monoklonaler antikörper, hybridome, ihre herstellung und verwendung | |
JP3107248B2 (ja) | 抗体および免疫化学的測定法 | |
US5187062A (en) | Method for detecting and measuring FGF | |
JP3232415B2 (ja) | モノクローナル抗体,その製造法および用途 | |
AU593063B2 (en) | Purified human angiogenic factor, method for its preparation and pharmaceutical preparations | |
EP0387777A2 (de) | Verfahren zum Nachweis von FGF und zur Diagnose von Tumoren | |
JPH06125784A (ja) | モノクローナル抗体,ハイブリドーマ,その製造法および用途 | |
JPH0315758A (ja) | 線維芽細胞増殖因子の検出・測定法および腫瘍の診断法 | |
JPH02306996A (ja) | 酸性線維芽細胞成長因子の抗体,その用途およびペプチド | |
JP3024987B2 (ja) | 抗体、その製造法および用途 | |
Adolf et al. | Highly sensitive enzyme immunoassay for human lymphotoxin (tumor necrosis factor β) in serum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19920623 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19950222 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19970107 |